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Abstract: Background: The incidence of venous thromboembolism (VTE) in children has been increasing.
Anticoagulants are the mainstay of treatment but are associated with bleeding events that may be life-
threatening. Idarucizumab is a fragment antigen-binding (fab) that provides immediate, complete, and
sustained reversal of dabigatran’s anticoagulant effects in adults. Objective and Methods: This phase III,
open-label, single-arm, multicenter, multinational trial will assess the safety of idarucizumab in children
participating in two ongoing trials investigating dabigatran etexilate. Eligible patients will be children
with VTE (aged 0-฀18 years; n = 5) with life-threatening or uncontrolled bleeding (group A), and children
who require emergency surgery/urgent procedures for a condition other than bleeding (group B). Patients
will receive idarucizumab up to 5 g as two consecutive intravenous infusions over 5-10 minutes each, as two
10-15-minute drips or as two bolus injections (15 minutes apart) and will be monitored for 30 days. The
primary endpoint will be the safety of idarucizumab assessed by the occurrence of drug-related adverse
events (including immune reactions) and all-cause mortality. Secondary endpoints will be the reversal of
dabigatran anticoagulant effects assessed by changes in diluted thrombin time and ecarin clotting time,
time to achieve complete reversal and the duration of the reversal and bleeding severity (group A). The
formation of antidrug antibodies at 30 days post-dose and cessation of bleeding will also be assessed.
Conclusion: This study will report the safety of idarucizumab in children with VTE who require rapid
reversal of the anticoagulant effects of dabigatran. Clinical trial registration: NCT02815670.
DOI: https://doi.org/10.1002/rth2.12053
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increasing.	 Anticoagulants	 are	 the	 mainstay	 of	 treatment	 but	 are	 associated	 with	
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1  | INTRODUCTION
The	 incidence	 of	 venous	 thromboembolism	 (VTE)	 in	 children	 has	
been	 increasing	 over	 time.1	 Anticoagulants	 such	 as	 unfraction-
ated	heparin,	 low-	molecular-	weight	 heparin	 (LMWH),	 and	vitamin	
K	 antagonists	 (VKAs)	 are	widely	 used	 therapeutic	 options	 for	 the	
treatment	and	prevention	of	VTE,	albeit	with	some	disadvantages.	
LMWH,	 for	 example,	 is	 administered	 by	 subcutaneous	 injection,	
VKAs	 require	 intensive	 anticoagulation	monitoring,	 and	 are	 asso-
ciated	 with	 multiple	 food	 and	 drug	 interactions.2 The direct oral 
	anticoagulants	 (DOACs),	 such	 as	 dabigatran	 etexilate,	 overcome	
many	 of	 the	 shortcomings	 associated	with	 the	 use	 of	 the	 current	
standard	 of	 care	 for	VTE,	 namely	 LMWHs	 and	VKAs.	 Dabigatran	








With	 the	 increasing	 use	 of	 anticoagulants,	 there	 is	 an	 unmet	
need	 for	 agents	 that	 can	 reverse	 anticoagulant	 effects	 in	 patients	
who	 require	 emergency	 surgery	 or	 urgent	 procedures,	 or	who	have	










Currently,	 dabigatran	 is	 the	 only	 DOAC	 to	 have	 a	 compound-	
specific	 reversal	 agent	 (idarucizumab)	 approved	 for	 use	 in	 adults.	
Idarucizumab	 is	 a	 monoclonal	 antibody	 fragment	 that	 binds	 spe-





yet to be established in children.
1.1 | Study objective
We	present	here	the	design	of	a	trial	that	will	evaluate	the	safety	
and	 efficacy	 of	 idarucizumab	 in	 children	 aged	 ≤18	years	who	 are	
being	treated	with	dabigatran	etexilate	within	the	ongoing	pediatric	
clinical	 trials	 for	 treatment	 (NCT01895777)	or	 secondary	preven-
tion	(NCT02197416)	of	VTE,	and	who	require	emergency	surgery/












in	 all	 patients.	 The	 assessments	 performed	 at	 each	 time-	point	 are	
 described in Table 1.






mendations	 to	 the	 sponsor	 regarding	 continuation,	 modification	 or	
termination	of	the	study	(Figure	1).
The	 trial	will	 be	 carried	 out	 in	 compliance	with	 the	 approved	
protocol	 and	 the	 ethical	 principles	 laid	 down	 in	 the	 Declaration	
of	 Helsinki,	 in	 accordance	 with	 the	 International	 Council	 on	
Harmonisation	 of	 Technical	 Requirements	 for	 Registration	 of	
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TABLE  1 Specific	assessments	carried	out	at	each	visit	during	the	study
Trial period/
procedure Screening Treatment period Follow- up period












X X X X X X
Surgery/procedure	
assessment
X X X X X X
Drug	
administration
– X X – – –




– X X X – –
ADA	blood	
samplec
– X – – – X









































safety and efficacy data;
advise sponsor on whether
to continue, modify,
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2.3 | Participants
The	 following	 patients	 will	 be	 eligible	 to	 enter	 the	 present	 study.	
Patients	receiving	dabigatran	etexilate	for	the	treatment	and	second-
ary	prevention	of	VTE	in	the	ongoing	pediatric	trials	NCT01895777	









venous	 line	 is	 not	 required.	 Idarucizumab	may	 be	 given	 through	 an	
existing	intravenous	line	infusing	with	0.9%	normal	saline	only,	inter-
mittent	intravenous	lock,	peripheral	intravenous,	or	a	central	venous	
catheter.	A	 dose	of	 5	g	 of	 idarucizumab	was	 chosen	 as	 a	 reference	
dose	because	it	 is	sufficient	to	reverse	the	body	loads	of	dabigatran	
measured	 in	 adults.	 Idarucizumab	 binds	 and	 inactivates	 dabigatran	
following	a	1:1	stoichiometry.	Assuming	that	dabigatran	plasma	con-









The	 full	 list	of	primary	and	secondary	 study	endpoints	 is	presented	
in	 Table	3.	 The	 primary	 endpoint	 is	 to	 assess	 the	 safety	 of	 idaruci-
zumab	in	this	population.	The	investigators	will	collect	and	maintain	































All	 statistical	 analyses	 are	 descriptive	 in	 nature.	 The	 two	 patient	
groups	(groups	A	and	B)	will	be	summarized	separately	and	together,	
with	an	overall	conclusion,	if	possible.
Safety	 analyses	will	 be	 based	 on	 all	 treated	 patients	who	 have	
received	 any	 idarucizumab.	Occurrence	of	 drug-	related	AEs	 (includ-
ing	 immune	 reactions)	 and	 all-	cause	mortality	 during	 the	 trial	 (from	
the	 start	 of	 dosing	 until	 30	days	 after	 the	 end	 of	 dosing)	 will	 be	
	reported	using	descriptive	 statistics.	Potential	 specific	 risks,	 such	as	

























by	 listing	 the	 reversal	 values	 at	 planned	 time	 points.	 The	 cessation	
of	bleeding	will	be	reported	using	a	binary	yes/no	outcome	(group	A	
only).	Bleeding	status	and	other	clinical	conditions	that	may	contribute	










Dabigatran	 etexilate	 is	 indicated	 for	 stroke	 risk	 reduction	 in	 pa-
tients	with	 atrial	 fibrillation	 and	 in	 the	prevention	 and	 treatment	of	


























The	 current	 management	 of	 symptomatic	 bleeding	 associated	with	
dabigatran	has	 some	 similarities	 to	 that	 observed	 in	 patients	 taking	
VKA,	such	as	the	cessation	of	anticoagulant	treatment	and	the	use	of	




of	DOAC	effect	 is	 required.37	With	 the	approval	of	 idarucizumab,	 a	
dabigatran-	specific	 reversal	 agent,	 an	 additional	 treatment	 option	





anticoagulation	 in	 healthy	 volunteers,	 elderly	 patients,	 and	 patients	






following	 idarucizumab	 treatment.	 No	 bleeding	 complications	 were	
observed.	Only	two	out	of	12	patients	with	 ICH	showed	hematoma	
TABLE  3 Study	outcomes
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growth	and	the	mortality	rate	was	low	(6.5%).41	An	interim	analysis	of	
an	ongoing,	phase	III	trial	of	idarucizumab	in	dabigatran-	treated	adult	









age	VTE	 in	children	 is	unlicensed	or	off-	label,	 suggesting	a	paucity	
of	 clinical	data	 in	 children.	Therapeutic	 guidelines	 for	 treatment	of	
VTE	in	children	are	based	on	a	limited	number	of	small	pediatric	tri-
als	 but,	 in	many	 cases,	 the	 guidelines	 are	 extrapolated	 from	 adult	
studies,	which	may	 be	 inappropriate.37	 In	 addition,	 guidelines	 rec-
ommend	 generic	 methods,	 such	 as	 use	 of	 gastric	 lavage	 and	 oral	
activated	 charcoal	 in	 case	 of	 anticoagulant	 overdose,	 use	 of	 fresh	
frozen	plasma	or	activated	prothrombin	complex	concentrate	in	case	
of	serious	bleeding,	and	performing	dialysis	to	reverse	the	anticoag-
ulant	 effects	 of	 dabigatran.36,42	 Nevertheless,	 although	 experience	
is	very	 limited	with	 the	use	of	 reversal	agents	 in	children	receiving	







zumab	 approved	by	 the	European	Medicines	Agency	 requires	data	
generation	in	children.	Therefore,	there	is	a	need	to	conduct	trials	of	
reversal	 agents	 in	 children	 taking	 anticoagulants	who	may	develop	
















A	 secondary	 endpoint	 is	 coagulation-	time	 testing.	 These	 assays	
can	give	an	objective	measure	of	the	reversal	of	anticoagulation.	dTT	
and	 ECT	 are	 appropriate	 for	 dabigatran	 as	 the	 correlation	 between	
these	parameters	and	dabigatran	plasma	concentration	showed	a	high	
degree	of	linearity.36	Bleeding	assessment	is	a	more	subjective	metric,	

















Since	 DOACs	 are	 being	 considered	 as	 a	 potential	 replacement	
for	the	existing	standard	of	care	for	managing	children	with	VTE,	the	
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